				<b>0</b> , .20				
FORM (REV.	PTO-13	390 (Modified) U.S. PATENT AND TRADEN	IARK OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER				
•	TR	ANSMITTAL LETTER	TO THE UNITED STATES	P30,365 USA				
		DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
(	CON	ICERNING A SUBMISS	SION UNDER 35 U.S.C. 371	N/A 10 / 523864				
INTE	RNAT	TONAL APPLICATION NO. PCT/EP03/08812	INTERNATIONAL FILING DATE August 8, 2003	PRIORITY DATE CLAIMED August 8, 2002				
TITLE	E OF I	INVENTION						
USE	OF P	'APAVERINE-LIKE VASODIL	ATOR AND PHARMACEUTICAL COMI	POSITION				
		T(S) FOR DO/EO/US						
DOR	ЮТН	EA GROSS and FRANK HOLZ	ÆR					
Appli	cant h	erewith submits to the United State	es Designated/Elected Office (DO/EO/US) the	following items and other information:				
1.	$\boxtimes$	This is a FIRST submission of ite	ms concerning a submission under 35 U.S.C.	371.				
2.		This is a SECOND or SUBSEQU	ENT submission of items concerning a submis	ssion under 35 U.S.C. 371.				
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.						
4.		The US has been elected (Article	31).					
5.	$\boxtimes$	A copy of the International Applic	ation as filed (35 U.S.C. 371 (c)(2))					
		a. 🛛 is attached hereto (requ	ired only if not communicated by the Internation	onal Bureau).				
		b.  has been communicate	d by the International Bureau.					
		c.  is not required, as the a	pplication was filed in the United States Recei	ving Office (RO/US).				
6.	$\boxtimes$	An English language translation of	of the International Application as filed (35 U.S.	.C. 371(c)(2)).				
		a. 🛛 is attached hereto.						
		b.  has been previously su	bmitted under 35 U.S.C. 154(d)(4).					
7.	$\boxtimes$	Amendments to the claims of the	International Application under PCT Article 19	(35 U.S.C. 371 (c)(3))				
		a. 🛛 are attached hereto (red	quired only if not communicated by the Internal	tional Bureau).				
		b.  have been communicat	ed by the International Bureau.					
		c.  have not been made; he	owever, the time limit for making such amendn	nents has NOT expired.				
		d.   have not been made an	d will not be made.					
8.	×		of the amendments to the claims under PCT Ar	rticle 19 (35 U.S.C. 371(c)(3)).				
9.	×	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).						
10.		An English language translation of Article 36 (35 U.S.C. 371 (c)(5)).	of the annexes to the International Preliminary	Examination Report under PCT				
11.	⊠	A copy of the International Prelim	inary Examination Report (PCT/IPEA/409).					
12.	$\boxtimes$	A copy of the International Search	n Report (PCT/ISA/210).					
It	ems 1	3 to 23 below concern documen	t(s) or information included:					
13.			ment under 37 CFR 1.97 and 1.98.					
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
15.	$\boxtimes$	A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT preliminary amendment.						
17.		A substitute specification.						
18.		A power of attorney and/or change of address letter.						
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.						
20.		4,						
21.								
22.	⊠ SZ	•						
23.	×	Other items or information:	·					
		Application Data Sheet, USPTO F	Form 2038, Acknowledgment Postcard					

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATIO	N NO (if known, see	37 CFB 1.5)	INTERNATIONAL	INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER		
1	PCT/EP03/08812			P30,365 USA				
24. The following	fees are submitte	ed:				Applicant use	Office use	
🖾 a) Basic nat	ional fee				\$300.00	\$ \$300.00		
b) Examinat	ion fee	\$200.00	\$ \$200.00					
C) Search fe	e	\$ \$500.00						
	AL OF ABOVE	\$ \$1,000.00						
Additional fe sequence lis \$250 for each	e for specification ting or computer p h additional 50 sh							
Total Sheets			RATE					
- 100 =	/50 =				× \$250.00	\$ \$0.00		
	0.00 for furnishing riority date (37 C		eclaration later than n	nonth	s from the	\$		
CLAIMS	NUMBER F	ILED N	IUMBER EXTRA		RATE			
Total claims	9	- 20 =	0	x	\$50.00	\$ \$0.00		
Independent clair	ns 2	- 3=	0	x	\$200.00	\$ \$0.00		
MULTIPLE DEPE	NDENT CLAIMS	(if applicable)		+	\$360.00	\$ \$0.00		
		TOTA	L OF ABOVE C	ALC	ULATIONS =	\$ \$1,000.00		
☐ Applicant cla		tatus. See 37	CFR 1.27. The fees in	ndica	ted above are	\$ \$0.00		
				S	UBTOTAL =	\$ \$1,000.00		
	\$130.00 for furnised priority date (3		ish translation later th	an 30	months from	\$ \$0.00		
		•	TOTAL N	IATI	ONAL FEE =	\$ \$1,000.00		
Fee for recording accompanied by	the enclosed assi	\$ \$0.00						
			TOTAL FEE	ES E	NCLOSED =	\$ \$1,000.00		
-			Amou	nt to	be refunded:	1	\$	
			Amo	unt t	o be charged:		\$	
a. A check	in the amount of \$	;	to cover the a	bove	fees is enclosed			
	harge my Deposit ate copy of this sh		i	n the	amount of	to cove	er the above fees.	
	ctor is hereby auth	norized to cha	rge any additional fee A duplicate cop		•	red, or credit any overp osed.	ayment	
	•				•	ecome public. <b>Credit c</b> and authorization on F		
Information should not be included on this form. Provide credit card information and authorization on PTO-2038.  NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
	RESPONDENCE 1			•	1-+	-M. D. =	<del>//</del>	
Jonathan M. De	rmott, Ph.D.				SIGNATURE	<u> </u>		
Synnestvedt & I	•	leat Cture-t			Jonathan 1	Jonathan M. Dermott		
Philadelphia, PA	Tower, 1101 Mar \ 19107-2950	kei Sireei			NAME			
48,608								
REGISTRAT						ION NUMBER		

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)  Applicant(s): DOROTHEA GROSS and FRANK HOLZER  10 955273.864  P30,365 USA									
	T ·	DT01	Rosid PCT/PTC	005 USA 1 0 7 FEB 2005					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit					
N/A	Herewith	N/A	23307	N/A					
Invention: USE OF P	APAVERINE-LIKE VAS	ODILATOR AND PHARMACEUTIC	AL COMPOSITION	ON					
		· ·							
I hereby certify that	the following corresponde	ence:		<b></b>					
		Specification; 3) 4 sheets of drawings;							
		; 7) Int'l. Prel. Exam. Report; 8) Int'l. B; 11) Acknowledgment Postcard	Search Report; 9)	Declaration					
and rower of Attorn		dentify type of correspondence)							
is being deposited w		stal Service "Express Mail Post Office	to Addressee" se	ervice under 37					
		missioner for Patents, P.O. Box 1450							
		, , , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , , ,						
	February 7, 2005 (Date)								
		Cruz Ca	ılderon	•					
	Cruz Calderon  (Typed or Printed Name of Person Mailing Correspondence)								
		The Colonial Colonia	Inn-						
		(Signature of Person Mai	ling Correspondence)						
		EV45232	4025US						
		("Express Mail" Maile	ing Label Number)						
				:					
Note: Each paper must have its own certificate of mailing.									

## IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

## **VERIFICATION OF TRANSLATION**

I, Michael Wallace Richard Turner, Bachelor of Arts, Chartered Patent Attorney, European Patent Attorney, of 1 Horsefair Mews, Romsey, Hampshire SO51 8JG, England, do hereby declare that I am conversant with the English and German languages and that I am a competent translator thereof;

I verify that the attached English translation is a true and correct translation made by me of the attached specification in the German language of International Application PCT/EP03/08812;

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: December 9, 2004

M W R Turner

MAdam